Navigation

Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine [ID320]

Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract

Status: History
Expected date of issue: December 2012
Referral date: March 2010
Process: STA
Topic area:
  • Cancer
  • Urogenital
 

NICE project team

Executive Lead: Carole Longson
Technical Lead: Mary Hughes
Communications manager: Alice Law
Project manager: Kate Moore
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 23 July 2010
1st appraisal committee meeting: 27 October 2010
2nd appraisal committee meeting 25 January 2011
3rd appraisal committee meeting: 25 September 2012
Top


 

Consultees and commentators

Consultees

 

Commentators (no right to submit or appeal)

 

Manufacturers/sponsors

  • Pierre Fabre (vinflunine)

Patient/carer groups

  • Macmillan Cancer Support

Professional groups

  • Action on Bladder Cancer
  • British Uro-oncology Group (BUG)
  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians
  • United Kingdom Oncology Nursing Society

Others

  • Department of Health
  • NHS Norfolk
  • Welsh Assembly Government

General

  • British National Formulary
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland

Comparator manufacturer(s)

  • None

Relevant research groups

  • Institute of Cancer Research

Evidence Review Group

  • Southampton Health Technology Assessment Centre
  • National Institute for Health Research Health Technology Assessment Programme

Associated Guideline Groups

  • National Collaborating Centre for Cancer

Associated Public Health Groups

  • None

Top


 

Project history

Date Update
6 July 2012

The Appeal Panel met on 23 May 2011 to consider the appeal lodged by Pierre Fabre against the Final Appraisal Determination (FAD) for this appraisal.  The appeal was upheld on the ground that during the course of the appraisal, there had been a redefinition of the patient population and vinflunine had been compared with (unlicensed) second line chemotherapy agents in a way that was inconsistent with the scope for the appraisal.

NICE have worked to address the appeal panel’s instructions and a further committee discussion will take place on 25 September 2012.

Top


 

Key documents

This page was last updated: 12 February 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.